Hangzhou Bio-Sincerity Pharma-Tech (301096.SZ) Receives Clinical Trial Approval for Innovative Drug BIOS-0625 Tablets

Stock News11-07

Hangzhou Bio-Sincerity Pharma-Tech Co., Ltd. (301096.SZ) announced that its self-developed innovative drug, BIOS-0625 tablets, has received clinical trial approval from the National Medical Products Administration (NMPA). Ulcerative colitis, a chronic relapsing inflammatory bowel disease, presents persistent treatment challenges due to its incurable and recurrent nature. While traditional medications offer short-term symptom relief, they face three major limitations: limited efficacy, significant adverse effects, and poor patient tolerance. New molecules and therapies serve as the cornerstone for improving patients' quality of life and act as a critical bridge between translational medicine and long-term patient benefits. BIOS-0625 tablets, developed by the company, target a novel mechanism for treating ulcerative colitis, with no currently approved drugs sharing the same indication. Classified as a Category 1 chemical drug, BIOS-0625 represents an innovative therapy not yet marketed domestically or internationally.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1199628935?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-07 20:42","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1199628935","market":"sh","top_or_hot":-1,"title":"Hangzhou Bio-Sincerity Pharma-Tech (301096.SZ) Receives Clinical Trial Approval for Innovative Drug BIOS-0625 Tablets","media":"Stock News","content":"<p>Hangzhou Bio-Sincerity Pharma-Tech Co., Ltd. (301096.SZ) announced that its self-developed innovative drug, BIOS-0625 tablets, has received clinical trial approval from the National Medical Products Administration (NMPA). Ulcerative colitis, a chronic relapsing inflammatory bowel disease, presents persistent treatment challenges due to its incurable and recurrent nature. While traditional medications offer short-term symptom relief, they face three major limitations: limited efficacy, significant adverse effects, and poor patient tolerance. New molecules and therapies serve as the cornerstone for improving patients' quality of life and act as a critical bridge between translational medicine and long-term patient benefits. BIOS-0625 tablets, developed by the company, target a novel mechanism for treating ulcerative colitis, with no currently approved drugs sharing the same indication. Classified as a Category 1 chemical drug, BIOS-0625 represents an innovative therapy not yet marketed domestically or internationally.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hangzhou Bio-Sincerity Pharma-Tech (301096.SZ) Receives Clinical Trial Approval for Innovative Drug BIOS-0625 Tablets</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHangzhou Bio-Sincerity Pharma-Tech (301096.SZ) Receives Clinical Trial Approval for Innovative Drug BIOS-0625 Tablets\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-11-07 20:42</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Hangzhou Bio-Sincerity Pharma-Tech Co., Ltd. (301096.SZ) announced that its self-developed innovative drug, BIOS-0625 tablets, has received clinical trial approval from the National Medical Products Administration (NMPA). Ulcerative colitis, a chronic relapsing inflammatory bowel disease, presents persistent treatment challenges due to its incurable and recurrent nature. While traditional medications offer short-term symptom relief, they face three major limitations: limited efficacy, significant adverse effects, and poor patient tolerance. New molecules and therapies serve as the cornerstone for improving patients' quality of life and act as a critical bridge between translational medicine and long-term patient benefits. BIOS-0625 tablets, developed by the company, target a novel mechanism for treating ulcerative colitis, with no currently approved drugs sharing the same indication. Classified as a Category 1 chemical drug, BIOS-0625 represents an innovative therapy not yet marketed domestically or internationally.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1161","symbol_name":"生物科技","start_time":0,"source_url":"","article_id":"1199628935","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1199628935","pubTimestamp":1762519331,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Hangzhou Bio-Sincerity Pharma-Tech Co., Ltd. (301096.SZ) announced that its self-developed innovative drug, BIOS-0625 tablets, has received clinical trial approval from the National Medical Products...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"159992":"创新药","301096":"百诚医药","BK1161":"生物科技","BK1574":"生物医药B类股","BK0216":"研究试验","06978":"永泰生物-B"},"translate_title":"杭州生物诚意药业（301096.SZ）获得创新药BIOS-0625片临床试验批件","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159992":1,"301096":1,"06978":1},"content_text":"Hangzhou Bio-Sincerity Pharma-Tech Co., Ltd. (301096.SZ) announced that its self-developed innovative drug, BIOS-0625 tablets, has received clinical trial approval from the National Medical Products Administration (NMPA). Ulcerative colitis, a chronic relapsing inflammatory bowel disease, presents persistent treatment challenges due to its incurable and recurrent nature. While traditional medications offer short-term symptom relief, they face three major limitations: limited efficacy, significant adverse effects, and poor patient tolerance. New molecules and therapies serve as the cornerstone for improving patients' quality of life and act as a critical bridge between translational medicine and long-term patient benefits. BIOS-0625 tablets, developed by the company, target a novel mechanism for treating ulcerative colitis, with no currently approved drugs sharing the same indication. Classified as a Category 1 chemical drug, BIOS-0625 represents an innovative therapy not yet marketed domestically or internationally.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1199628935","isCrawlerRequest":true}